drugset / Trial / NCT07172022
A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy of crovalimab compared with placebo as an add-on therapy to vitamin K antagonist (VKA) in participants with APS.
Timeline
- Start
- 2026-03-16
- Primary completion
- 2030-03-11
- Completion
- 2030-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crovalimab | Monoclonal antibody | 680 mg | Subcutaneous |
| Subject | Crovalimab | Monoclonal antibody | 1020 mg | Subcutaneous |